{"nctId":"NCT01352793","briefTitle":"A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years","startDateStruct":{"date":"2012-11"},"conditions":["Meningitis, Meningococcal"],"count":5715,"armGroups":[{"label":"rLP2086 vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: rLP2086 vaccine"]},{"label":"control","type":"OTHER","interventionNames":["Biological: control"]}],"interventions":[{"name":"rLP2086 vaccine","otherNames":[]},{"name":"control","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy subjects aged 10 to 25 years.\n\nExclusion Criteria:\n\n* Previous vaccination with Hepatitis A virus vaccine\n* Previous vaccination with investigational meningococcal B vaccine\n* History of culture-proven N. meningitidis serogroup B disease\n* Any neuroinflammatory or autoimmune condition\n* Any immune defect that would prevent an effective response to the study vaccine","healthyVolunteers":true,"sex":"ALL","minimumAge":"10 Years","maximumAge":"25 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With at Least One Serious Adverse Event (SAE) Throughout the Study","description":"An adverse event (AE) was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":null},{"groupId":"OG001","value":"2.52","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 1","description":"A medically attended AE was defined as a non-serious AE that required medical attention.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.03","spread":null},{"groupId":"OG001","value":"6.13","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 2","description":"A medically attended AE was defined as a non-serious AE that required medical attention.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.50","spread":null},{"groupId":"OG001","value":"6.09","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 3","description":"A medically attended AE was defined as a non-serious AE that required medical attention.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.34","spread":null},{"groupId":"OG001","value":"5.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least One Serious Adverse Event (SAE) During Pre-specified Time Periods","description":"An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Here, 'N' signifies those participants who were evaluable for this measure during specified time period.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":null},{"groupId":"OG001","value":"0.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":null},{"groupId":"OG001","value":"0.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":null},{"groupId":"OG001","value":"0.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":null},{"groupId":"OG001","value":"0.94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":null},{"groupId":"OG001","value":"1.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":null},{"groupId":"OG001","value":"0.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least One Medically Attended Adverse Event During Pre-specified Time Periods","description":"A medically attended AE was defined as a non-serious AE that required medical attention.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.38","spread":null},{"groupId":"OG001","value":"14.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.60","spread":null},{"groupId":"OG001","value":"24.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.24","spread":null},{"groupId":"OG001","value":"11.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.00","spread":null},{"groupId":"OG001","value":"29.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least One Newly Diagnosed Chronic Medical Condition During Pre-specified Time Periods","description":"A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions. Here, 'N' signifies those participants who were evaluable for this measure during specified time period.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":null},{"groupId":"OG001","value":"0.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":null},{"groupId":"OG001","value":"0.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":null},{"groupId":"OG001","value":"0.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":null},{"groupId":"OG001","value":"0.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":null},{"groupId":"OG001","value":"1.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":null},{"groupId":"OG001","value":"0.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":null},{"groupId":"OG001","value":"1.52","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least One Adverse Event (AE) During Pre-specified Time Periods","description":"An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. Here, 'N' signifies those participants who were evaluable for this measure during specified time period.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.48","spread":null},{"groupId":"OG001","value":"19.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.37","spread":null},{"groupId":"OG001","value":"12.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.00","spread":null},{"groupId":"OG001","value":"10.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.02","spread":null},{"groupId":"OG001","value":"31.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.08","spread":null},{"groupId":"OG001","value":"42.51","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least One Immediate Adverse Event (AE) After Each Study Vaccination","description":"An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. Any AE that occurred within the first 30 minutes after the administration of study vaccine (bivalent rLP2086, HAV vaccine or saline) was classified as an immediate AE. Here, 'N' signifies those participants who were evaluable for this measure during specified time period.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":null},{"groupId":"OG001","value":"0.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":null},{"groupId":"OG001","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":null},{"groupId":"OG001","value":"0.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days Participant Missed School or Work Due to Adverse Events (AEs)","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"7.01"},{"groupId":"OG001","value":"3.0","spread":"9.67"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":59,"n":3796},"commonTop":["Injection site pain","Headache","Pyrexia","Upper respiratory tract infection","Nasopharyngitis"]}}}